Business Standard

CCI rules in favour of Biocon in case against Roche over breast cancer drug

Biocon and Mylan started marketing biosimilars of Roche's Trastuzumab drug in 2014

Biocon
Premium

Biocon

Veena Mani New Delhi
The Competition Commission of India (CCI) has given directions for carrying out a detailed investigation to ascertain if Roche used its dominant position to maintain its monopoly over the breast cancer drug Trastuzumab.  

The order comes as a response to a joint complaint filed by the Mylan and Biocon in 2016 alleging that the Roche Group indulged in "abusive conduct".

"The Commission is of the considered view that, prima facie, the contravention with regard to Section 4(2)(c) of the Act is made out against Roche Group, which warrants a detailed investigation into the matter. The DG is, thus,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in